Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$5.20
-0.25-4.59%
At Close: -
$5.35
0.152.88%
After Hours: 4:49 PM EDT
15 minutes delayed
Comments
Loading...
Humacyte (NASDAQ:HUMA) Stock, Analyst Ratings, Price Targets, Forecasts
Humacyte Inc has a consensus price target of $12.22 based on the ratings of 9 analysts. The high is $25 issued by EF Hutton on September 9, 2024. The low is $3 issued by Piper Sandler on November 10, 2023. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, EF Hutton, and Benchmark on September 20, 2024, September 9, 2024, and September 5, 2024, respectively. With an average price target of $17.67 between Cantor Fitzgerald, EF Hutton, and Benchmark, there's an implied 230.22% upside for Humacyte Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
EF Hutton
Benchmark
BTIG
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Humacyte
Data brought to you by Benzinga APIs
FAQ
What is the target price for Humacyte (HUMA) stock?
The latest price target for Humacyte (NASDAQ:HUMA) was reported by Cantor Fitzgerald on September 20, 2024. The analyst firm set a price target for $13.00 expecting HUMA to rise to within 12 months (a possible 142.99% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Humacyte (HUMA)?
The latest analyst rating for Humacyte (NASDAQ:HUMA) was provided by Cantor Fitzgerald, and Humacyte reiterated their overweight rating.
When was the last upgrade for Humacyte (HUMA)?
There is no last upgrade for Humacyte
When was the last downgrade for Humacyte (HUMA)?
There is no last downgrade for Humacyte.
When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on September 20, 2024 so you should expect the next rating to be made available sometime around September 20, 2025.
Is the Analyst Rating Humacyte (HUMA) correct?
While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $13.00 to $13.00. The current price Humacyte (HUMA) is trading at is $5.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.